Table 1 Characteristics of ESPOIR RA patients at inclusion
From: Reduced progression of bone erosion in cytomegalovirus seropositive rheumatoid arthritis patients
ESPOIR cohort | ||||
|---|---|---|---|---|
All RA patients (n = 487) | HCMV seropositive RA patients (n = 273) (56%) | HCMV seronegative RA patients (n = 214) (44%) | p (HCMV+ versus HCMV−) | |
Baseline characteristics (inclusion) | ||||
Age, years, median (IQR)*** | 50.3 (40.0–57.1) | 52.9 (43.1–58.5)*** | 47.8 (37.4–54.3) | 0.0001 |
Gender, female, n (%) | 378 (77.6) | 219 (80.2) | 159 (74.3) | 0.1197 |
Symptom duration, year, median (IQR) | 0.42 (0.26–0.64) | 0.41 (0.25–0.62) | 0.42 (0.27–0.65) | 0.5108 |
ACPA+, n (%)* | 262 (53.8) | 136 (49.8)* | 126 (58.9) | 0.0465 |
RF+, n (%) | 296 (60.8) | 163 (59.7) | 133 (62.1) | 0.5837 |
Disease Activity Score 28 (DAS28-ESR), mean (IQR)* | 5.40 (± 1.21) | 5.55 (± 1.24)* | 5.20 (± 1.14) | 0.0013 |
Erythrocyte sedimentation rate (ESR), median (IQR) | 24 (12–39) | 24 (14–46) | 22.5 (10.5–35.5) | 0.0566 |
C-reactive protein (CRP), median (IQR) | 10 (3–24) | 9 (3–24) | 11 (3–24) | 0.5510 |
Total Sharp score (TSS), median (IQR) | 4 (1–8) | 4 (1–8) | 3 (1–8) | 0.6745 |
Erosion Sharp score (ESS), median (IQR) | 1 (0–4) | 1 (0–4) | 1 (0–4) | 0.5420 |
Joint space narrowing Sharp score (NSS), median (IQR) | 1 (0–4) | 1 (0–4) | 1 (0–4) | 0.9121 |